Viking Excites With Latest Oral VK2735 Weight Loss Data
CinFina Advances Next-Generation Obesity Drugs
Viking’s dual GLP-1/GIP agonist VK2735 continues to make headlines for strong efficacy and tolerability with oral and injectable formulations. CinFina reports progress with two new MOAs.
